Literature DB >> 2229380

Comparison of four Mycoplasma arthritidis strains by enzyme immunoassay, metabolism inhibition, one- and two-dimensional electrophoresis, and immunoblotting.

L R Washburn1, S Hirsch.   

Abstract

Four Mycoplasma arthritidis strains, two virulent (158p10p9 and 14124p10) and two avirulent (PG6 and H606), were examined for differences in their antigenic compositions. Rabbit antisera prepared against each strain were compared for their reactivities against both homologous and heterologous strains by enzyme-linked immunosorbent assay and metabolism inhibition assay. These tests confirmed a close serologic relationship among the four strains. Only by cross-absorbing each antiserum with intact cells from both homologous and heterologous strains could serologic differences be detected. Interestingly, antigenic variability was minimal among those antigens involved in the metabolism inhibition reaction, suggesting that they may be highly conserved within this species. No differences in protein composition could be detected by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis. However, slight variation was apparent on two-dimensional gels, and antigens possessing strain-specific epitopes were detected by two-dimensional immunoblotting experiments performed with cross-absorbed antisera. The enzyme-linked immunosorbent assay, two-dimensional electrophoresis, and immunoblotting experiments showed that the two virulent strains were closely related to each other, while the avirulent strains were more distantly related to each other and to the other two strains. The relationship of M. arthritidis serologic diversity to virulence remains unclear: however, this study has demonstrated that it may be possible to subdivide M. arthritidis into serogroups on the basis of cross-absorption patterns and to identify those antigens bearing strain-specific epitopes by immunoblotting with cross-absorbed antisera.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229380      PMCID: PMC268089          DOI: 10.1128/jcm.28.9.1974-1981.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Experimental polyarthritis in rats produced by Mycoplasma arthritidis.

Authors:  A Hill; G J Dagnall
Journal:  J Comp Pathol       Date:  1975-01       Impact factor: 1.311

2.  BIOCHEMICAL, MORPHOLOGICAL, AND SEROLOGICAL CHARACTERIZATION OF MYCOPLASMA OF MURINE ORIGIN.

Authors:  J G TULLY
Journal:  J Infect Dis       Date:  1965-04       Impact factor: 5.226

3.  Heat-lability and organic solvent-solubility of mycoplasma antigens.

Authors:  G E Kenny
Journal:  Ann N Y Acad Sci       Date:  1967-07-28       Impact factor: 5.691

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Characterization of the metabolism inhibition antigen of Mycoplasma arthritidis.

Authors:  L R Washburn; J R Ramsay; L K Roberts
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

6.  Antigenic differences within the species Mycoplasma hominis.

Authors:  M R Hollingdale; R M Lemcke
Journal:  J Hyg (Lond)       Date:  1970-09

7.  An antigenic analysis for membranes of Mycoplasma hominis by cross-absorption.

Authors:  J S Lin
Journal:  J Gen Microbiol       Date:  1980-01

8.  Chronic proliferative arthritis of mice induced by Mycoplasma arthritidis. I. Induction of disease and histopathological characteristics.

Authors:  B C Cole; J R Ward; R S Jones; J F Cahill
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

9.  Chronic arthritis of rabbits induced by mycoplasmas. I. Clinical microbiologic, and histologic features.

Authors:  L R Washburn; B C Cole; M I Gelman; J R Ward
Journal:  Arthritis Rheum       Date:  1980-07

10.  Immunological responses of the rat to Mycoplasma arthritidis.

Authors:  B C Cole; J F Cahill; B B Wiley; J R Ward
Journal:  J Bacteriol       Date:  1969-06       Impact factor: 3.490

View more
  8 in total

1.  Molecular characterization of Mycoplasma arthritidis variable surface protein MAA2.

Authors:  L R Washburn; K E Weaver; E J Weaver; W Donelan; S Al-Sheboul
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

2.  Protection of rats against Mycoplasma arthritidis-induced arthritis by active and passive immunizations with two surface antigens.

Authors:  L R Washburn; E J Weaver
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

3.  A family of phase- and size-variant membrane surface lipoprotein antigens (Vsps) of Mycoplasma bovis.

Authors:  A Behrens; M Heller; H Kirchhoff; D Yogev; R Rosengarten
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

4.  Association of lysogenic bacteriophage MAV1 with virulence of Mycoplasma arthritidis.

Authors:  L L Voelker; K E Weaver; L J Ehle; L R Washburn
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

5.  Antigen heterogeneity among isolates of Mycoplasma bovis is generated by high-frequency variation of diverse membrane surface proteins.

Authors:  R Rosengarten; A Behrens; A Stetefeld; M Heller; M Ahrens; K Sachse; D Yogev; H Kirchhoff
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  The Vlp system of Mycoplasma hyorhinis: combinatorial expression of distinct size variant lipoproteins generating high-frequency surface antigenic variation.

Authors:  R Rosengarten; K S Wise
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

7.  Mechanisms of attachment of Mycoplasma arthritidis to host cells in vitro.

Authors:  L R Washburn; S Hirsch; L L Voelker
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

8.  Comparison of Mycoplasma arthritidis strains by enzyme-linked immunosorbent assay, immunoblotting, and DNA restriction analysis.

Authors:  L R Washburn; L L Voelker; L J Ehle; S Hirsch; C Dutenhofer; K Olson; B Beck
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.